and is also in trials for Crohn’s and primary biliary cholangitis. Meanwhile, there are drugs in other classes jostling for market share for UC, including biologics like TNF inhibitors and ...

Tepezza was recently approved in Japan for treatment of active or high clinical activity score thyroid eye disease ... For example, primary biliary cholangitis drug seladelpar has gained ...

approved by the U.S. Food and Drug Administration for the treatment of primary biliary cholangitis. It is also the major active component of bear bile used in traditional Chinese medicine to reduce ...

Livdelzi (seladelpar) is a medicine that can treat primary biliary cholangitis (PBC) by reducing the amount of bile in your body. It does this by signaling the body to stop making bile acid.

Gilead Sciences’ Livdelzi (seladelpar) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with the rare liver disease primary biliary cholangitis (PBC) ...

Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).

Medically reviewed by Jay N. Yepuri, MD Primary sclerosing cholangitis (PSC) is a progressive scarring of the liver's bile ...

Primary biliary cirrhosis (PBC ... and primary sclerosing cholangitis (PSC). The most frequent ANA patterns in PBC sera are the 'speckled' (Figure 1), the multiple nuclear dots (MND; Figure ...

Objectives Primary sclerosing cholangitis (PSC) is a rare chronic disease that presents challenges to both patients and ...